TP53 is frequently mutated in a variety of human cancers, and hematological neoplasms, including myelodysplastic syndrome (MDS), multiple myeloma (MM), acute and chronic leukemias (e.g., AML, ALL, CML, CLL), and lymphomas are not exceptions [13–18]. Here, TP53 is linked to plasma cell myeloma.